Eye docs confront Genentech exec

Put a Genentech executive and a bunch of angry ophthalmologists in the same room, and what do you get? Fireworks. At a conference over the weekend, the company's president of product development, Susan Desmond-Hellman, defended its decision to stop selling Avastin to compounding pharmacies, which repackage the drug for use against macular degeneration.

Desmond-Hellman blamed the move on the FDA, saying, "[w]e had no choice." The FDA's worries about repackaging the cancer med could "put our entire manufacturing operation at risk." That's funny, the eye docs responded. The FDA told us different.

Genentech believes eye docs will still be able to get Avastin for their WMD patients. And Desmond-Hellman vigorously denied that the move was meant to steer patients toward the company's designated WMD drug Lucentis, which runs $2,000 a dose compared with $40 for Avastin.

- read the release from the American Academy of Ophthalmology
- see this the item and from the Wall Street Journal's Health Blog
- read the report from OSN SuperSite

Related Articles:
Genentech rethinks Avastin limits. Report
Why should Medicare pay for Lucentis? Report
Genentech cuts eye docs out of Avastin. Report
Doctors balancing effects, costs of Lucentis and Avastin. Report
Lucentis gets the green light from regulators. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.